Cargando…

Ciprofloxacin dry powder inhaler in cystic fibrosis

Detalles Bibliográficos
Autor principal:	Elborn, J Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716192/ https://www.ncbi.nlm.nih.gov/pubmed/26835137 http://dx.doi.org/10.1136/bmjresp-2015-000125

Ejemplares similares

Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study
por: Wilson, Robert, et al.
Publicado: (2013)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Modulator treatment for people with cystic fibrosis: moving in the right direction
por: Elborn, J. Stuart
Publicado: (2020)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis
por: Chorepsima, Stamatia, et al.
Publicado: (2018)

Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study
por: Stass, Heino, et al.
Publicado: (2013)

Inspiratory Flows and Volumes in Subjects with Cystic Fibrosis Using a New Dry Powder Inhaler Device
por: Elkins, Mark R., et al.
Publicado: (2014)

The effect of ethanol on the habit and in vitro aerodynamic results of dry powder inhalation formulations containing ciprofloxacin hydrochloride
por: Benke, Edit, et al.
Publicado: (2021)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients
por: Hoppentocht, Marcel, et al.
Publicado: (2016)

Stability of Inhaled Ciprofloxacin-Loaded Poly(2-ethyl-2-oxazoline) Nanoparticle Dry Powder Inhaler Formulation in High Stressed Conditions
por: Sabuj, Mohammad Zaidur Rahman, et al.
Publicado: (2022)

Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach
por: Karimi, Keyhaneh, et al.
Publicado: (2016)

Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study
por: Martínez-García, Miguel Ángel, et al.
Publicado: (2020)

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis
por: Lu, Peng, et al.
Publicado: (2022)

Protein biomarkers in cystic fibrosis research: where next?
por: Pattison, Sally H, et al.
Publicado: (2010)

Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections
por: Sabuj, Mohammad Zaidur Rahman, et al.
Publicado: (2021)

Digital healthcare in cystic fibrosis. Learning from the pandemic to innovate future care (Commentary)()
por: Elborn, J Stuart
Publicado: (2021)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study
por: van Koningsbruggen-Rietschel, Silke, et al.
Publicado: (2020)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data
por: Hamed, Kamal, et al.
Publicado: (2017)

Targeted therapies to improve CFTR function in cystic fibrosis
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis
por: Chennakesavulu, S., et al.
Publicado: (2018)

Organisms isolated from adults with Cystic Fibrosis
por: McManus, Terence E, et al.
Publicado: (2004)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler
por: Allan, Richard, et al.
Publicado: (2021)

Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations
por: Miyamoto, Kahori, et al.
Publicado: (2022)

Feedback systems in multi-dose dry powder inhalers
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Effect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations
por: Raut, Neha Sureshrao, et al.
Publicado: (2016)

Appropriate use of a dry powder inhaler based on inhalation flow pattern
por: Kondo, Tetsuri, et al.
Publicado: (2017)

The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
por: Harvey, Caitlyn, et al.
Publicado: (2022)

Inhaled Biologicals for the Treatment of Cystic Fibrosis
por: Sala, Valentina, et al.
Publicado: (2019)

Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial
por: Serisier, David J, et al.
Publicado: (2013)

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
por: Sahakijpijarn, Sawittree, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t5diorhim67v18qssba6nn80s6